Tuesday - April 7, 2026
Acoziborole Winthrop, Developed by DNDi and Sanofi, Receives CHMP Positive Opinion as Three-Tablet, Single-Dose Treatment for Most Common Form of Sleeping Sickness
February 28, 2026
PARIS, France, Feb. 28 -- Sanofi, a life sciences company, issued the following news release:

* * *

Press Release: Acoziborole Winthrop, developed by DNDi and Sanofi, receives CHMP positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness

Acoziborole Winthrop, developed by DNDi and Sanofi, receives CHMP positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness

* Re . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products